Patents by Inventor Viktor Magdolen

Viktor Magdolen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KLK4 inhibitors
    Patent number: 10017527
    Abstract: The present invention relates to novel compounds and probes which have a common chemical structure necessary to obtain potent inhibitory activity against KLK4 and/or may be used for the detection of KLK4 peptides and their activity. It further relates to the use of these compounds and methods for inhibiting and/or detecting KLK4 activity in vitro and in vivo by making use of said probes or inhibitors. The compounds of the invention differ from prior art compounds at least in the presence of phenyl guanidine (instead of e.g. benzyl guanidine) and/or the presence of a heteroatom in the tail group, their combined presence unexpectedly leading to potent and selective KLK4 inhibitory activity.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: July 10, 2018
    Assignee: UNIVERSITEIT ANTWERPEN
    Inventors: Jurgen Joossens, Koen Augustyns, Anne-Marie Lambeir, Pieter Van Der Veken, Jeroen Van Soom, Viktor Magdolen
  • NOVEL KLK4 INHIBITORS
    Publication number: 20170101427
    Abstract: The present invention relates to novel compounds and probes which have a common chemical structure necessary to obtain potent inhibitory activity against KLK4 and/or may be used for the detection of KLK4 peptides and their activity. It further relates to the use of these compounds and methods for inhibiting and/or detecting KLK4 activity in vitro and in vivo by making use of said probes or inhibitors. The compounds of the invention differ from prior art compounds at least in the presence of phenyl guanidine (instead of e.g. benzyl guanidine) and/or the presence of a heteroatom in the tail group, their combined presence unexpectedly leading to potent and selective KLK4 inhibitory activity.
    Type: Application
    Filed: March 30, 2015
    Publication date: April 13, 2017
    Applicant: UNIVERSITEIT ANTWERPEN
    Inventors: Jurgen JOOSSENS, Koen AUGUSTYNS, Anne-Marie LAMBEIR, Pieter VAN DER VEKEN, Jeroen VAN SOOM, Viktor MAGDOLEN
  • Nucleic acids encoding a deletion variant of uPAR
    Patent number: 8461321
    Abstract: This invention relates to the production of specific antibodies for the detection of human tumor associated urokinase-type plasminogen activator receptor (uPAR) deletion variants in biological samples as well as to their diagnostic and therapeutic application.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: June 11, 2013
    Assignee: Wilex AG
    Inventors: Thomas Luther, Viktor Magdolen, Manfred Schmitt, Bernd Muehlenweg, Matthias Kotzsch
  • Chimeric plasminogen activators and their pharmaceutical use
    Patent number: 8124588
    Abstract: The present invention relates to recombinant chimeric proteins comprising a surfactant protein precursor N-terminally fused to a plasminogen activator or comprising a mature surfactant protein N-terminally or C-terminally fused to a plasminogen activator. The invention is also directed to the corresponding nucleic acid molecules encoding such fusion proteins as well as to a method for their production. The invention further refers to a pharmaceutical composition comprising such a fusion protein and to pharmacological uses of an inventive fusion protein for the prevention and/or treatment of inflammatory and interstitial lung diseases.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: February 28, 2012
    Assignee: Justus Liebig Universität Giessen
    Inventors: Werner Seeger, Andreas Günther, Clemens Ruppert, Philipp Markart, Viktor Magdolen, Timothy E. Weaver
  • Novel chimeric plasminogen activators and their pharmaceutical use
    Publication number: 20090305961
    Abstract: The present invention relates to recombinant chimeric proteins comprising a surfactant protein precursor N-terminally fused to a plasminogen activator or comprising a mature surfactant protein N-terminally or C-terminally fused to a plasminogen activator. The invention is also directed to the corresponding nucleic acid molecules encoding such fusion proteins as well as to a method for their production. The invention further refers to a pharmaceutical composition comprising such a fusion protein and to pharmacological uses of an inventive fusion protein for the prevention and/or treatment of inflammatory and interstitial lung diseases.
    Type: Application
    Filed: December 18, 2003
    Publication date: December 10, 2009
    Inventors: Werner Seeger, Andreas Günther, Clemens Ruppert, Philipp Markart, Viktor Magdolen, Timothy E. Weaver
  • METHODS FOR THE DETECTION AND PROGNOSIS OF BREAST TUMORS
    Publication number: 20090202504
    Abstract: This invention relates to the production of specific antibodies for the detection of human tumor associated urokinase-type plasminogen activator receptor (uPAR) deletion variants in biological samples as well as to their diagnostic and therapeutic application.
    Type: Application
    Filed: June 30, 2008
    Publication date: August 13, 2009
    Applicant: WILEX AG
    Inventors: Thomas LUTHER, Viktor Magdolen, Manfred Schmitt, Bernd Muhlenweg, Matthias Kotzsch
  • Methods for the detection and prognosis of breast tumors
    Patent number: 7407751
    Abstract: This invention relates to the production of specific antibodies for the detection of human tumor associated urokinase-type plasminogen activator receptor (uPAR) deletion variants in biological samples as well as to their diagnostic and therapeutic application.
    Type: Grant
    Filed: October 6, 2003
    Date of Patent: August 5, 2008
    Assignee: Wilex AG
    Inventors: Thomas Luther, Viktor Magdolen, Manfred Schmitt, Matthias Kotzsch
  • Diagnostic and therapeutic use of antibodies against the urokinase receptor
    Patent number: 7399468
    Abstract: The invention concerns a method and a reagent kit for detecting cells in a biological sample using a double-fluorescence technique and the diagnostic and therapeutic application of amino acid sequence-specific antibodies against the urokinase receptor having a high affinity for tumour cell-expressed receptors.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: July 15, 2008
    Assignee: Wilex AG
    Inventors: Thomas Luther, Martin Mueller, Sybille Albrecht, Viktor Magdolen, Olaf Wilhelm, Manfred Schmitt, Nadja Harbeck
  • Urokinase inhibitors and uses thereof
    Patent number: 7342018
    Abstract: The invention relates to the use of derivatives of 3-amidinophenylalanine as urokinase inhibitors for treating malignant tumors and the formation of metastases.
    Type: Grant
    Filed: October 24, 2003
    Date of Patent: March 11, 2008
    Assignee: Wilex AG
    Inventors: Olaf Wilhelm, Viktor Magdolen, Jörg Stürzebecker, John Foekens, Verena Lutz
  • Selective inhibitors of the urokinase plasminogen activator
    Patent number: 7208521
    Abstract: The present invention relates to novel selective inhibitors of the urokinase plasminogene activator (uPA, EC3,4.21.31) of the aryl guanidine type.
    Type: Grant
    Filed: February 16, 2005
    Date of Patent: April 24, 2007
    Assignee: Wilex AG
    Inventors: Viktor Magdolen, Luis Moroder, Stefan Sperl, Jörg Stürzebecher, Olaf Wilhelm
  • Diagnostic and therapeutic use of antibodies against the urokinase receptor
    Publication number: 20070066798
    Abstract: The invention concerns a method and a reagent kit for detecting cells in a biological sample using a double-fluorescence technique and the diagnostic and therapeutic application of amino acid sequence-specific antibodies against the urokinase receptor having a high affinity for tumour cell-expressed receptors.
    Type: Application
    Filed: October 26, 2006
    Publication date: March 22, 2007
    Applicant: WILEX AG
    Inventors: Manfred Schmitt, Viktor Magdolen, Thomas Luther, Sybille Albrecht, Martin Muller, Olaf Wilhelm, Nadja Harbeck
  • Selective inhibitors of the urokinase plasminogen activator
    Patent number: 7049460
    Abstract: The present invention relates to novel selective inhibitors of the urokinase plasminogene activator (uPA, EC 3.4.21.31) of the aryl guanidine type.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: May 23, 2006
    Assignee: Wilex AG
    Inventors: Viktor Magdolen, Luis Moroder, Stefan Sperl, Jörg Stürzebecher, Olaf Wilhelm
  • Highly selective inhibitors of the urokinase plasminogen activator
    Patent number: 7049344
    Abstract: A method is described for inhibiting urokinase plasminogen activator in a human or animal patient.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: May 23, 2006
    Assignees: Wilex Biotechnology GmbH, Max-Planck-Gessellschaft zur Forderung der Wissenschaften E.V.
    Inventors: Viktor Magdolen, Stefan Sperl, Joerg Stuerzebecher, Olaf Wilhelm, Nuria Arroyo De Prada, Luis Moroder, Robert Huber, Uwe Jacob, Wolfram Bode
  • Selective inhibitors of the urokinase plasminogen activator
    Publication number: 20050215642
    Abstract: The present invention relates to novel selective inhibitors of the urokinase plasminogene activator (uPA, EC3,4.21.31) of the aryl guanidine type.
    Type: Application
    Filed: February 16, 2005
    Publication date: September 29, 2005
    Applicant: Wilex AG
    Inventors: Viktor Magdolen, Luis Moroder, Stefan Sperl, Jorg Sturzebecher, Olaf Wilhelm
  • Highly selective inhibitors of the urokinase plasminogen activator
    Publication number: 20050119348
    Abstract: A method is described for inhibiting urokinase plasminogen activator in a human or animal patient.
    Type: Application
    Filed: November 22, 2004
    Publication date: June 2, 2005
    Inventors: Viktor Magdolen, Stefan Sperl, Joerg Stuerzebecher, Olaf Wilhelm, Nuria Arroyo De Prada, Luis Moroder, Robert Huber, Uwe Jacob, Wolfram Bode
  • Inhibitors for urokinase receptor
    Patent number: 6872702
    Abstract: The present invention concerns peptides as inhibitors of the binding of urokinase to the urokinase receptor. These peptides, which are preferably cyclic, are suitable as pharmaceutical agents for diseases that are mediated by urokinase and its receptor.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: March 29, 2005
    Assignee: Wilex AG
    Inventors: Horst Kessler, Heinrich Graeff, Manfred Schmitt, Viktor Magdolen, Olaf G. Wilhelm, Christoph Riemer, Markus Bürgle
  • Highly selective inhibitors of the urokinase plasminogen activator
    Patent number: 6841702
    Abstract: The invention relates to novel selective inhibitors of the urokinase plasminogen activator (uPA, EC 3.4.21.31), of the arylguanidine type.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: January 11, 2005
    Assignees: Wilex Biotechnology GmbH, Max-Planck-Gesellschaft zur Forderung der Wissenschaften EV
    Inventors: Viktor Magdolen, Stefan Sperl, Joerg Stuerzebecher, Olaf Wilhelm, Nuria Arroyo De Prada, Luis Moroder, Robert Huber, Uwe Jacob, Wolfram Bode
  • Production of polyclonal, monospecific antibodies against the uPAR variants del4, del5, and del4and their use for diagnostic and therapeutic purposes
    Publication number: 20040197863
    Abstract: This invention relates to the production of specific antibodies for the detection of human tumor associated urokinase-type plasminogen activator receptor (uPAR) deletion variants in biological samples as well as to their diagnostic and therapeutic application.
    Type: Application
    Filed: October 6, 2003
    Publication date: October 7, 2004
    Applicant: WILEX AG
    Inventors: Thomas Luther, Viktor Magdolen, Manfred Schmitt, Bernd Muhlenweg, Matthias Kotzsch
  • Inhibitors of the urokinase receptor
    Publication number: 20040138110
    Abstract: The present invention concerns peptides as inhibitors of the binding of urokinase to the urokinase receptor. The peptides, which are preferably cyclic, are suitable as pharmaceutical agents for diseases that are mediated by urokinase and its receptor.
    Type: Application
    Filed: January 14, 2004
    Publication date: July 15, 2004
    Applicant: Wilex AG
    Inventors: Horst Kessler, Heinrich Graeff, Manfred Schmitt, Viktor Magdolen, Olaf G. Wilhelm, Christoph Riemer, Markus Burgle
  • Novel urokinase inhibitors
    Publication number: 20040138233
    Abstract: The invention relates to the use of derivatives of 3-amidinophenylalanine as urokinase inhibitors for treating malignant tumors and the formation of metastases.
    Type: Application
    Filed: October 24, 2003
    Publication date: July 15, 2004
    Applicant: WILEX AG
    Inventors: Olaf Wilhelm, Viktor Magdolen, Jorg Sturzebecker, John Foekens, Verena Lutz